期刊文献+

阿托伐他汀对急性冠状动脉综合征患者血浆B型钠尿肽水平的影响 被引量:6

Effect of atorvastatin on BNP levels in patients with acute coronary syndrome
原文传递
导出
摘要 目的探讨阿托伐他汀对急性冠状动脉综合征(ACS)患者血浆B型钠尿肽(BNP)水平的影响。方法选择青岛大学医学院第二附属医院2010年12月至2011年8月收治的ACS患者80例,随机分为观察组和对照组,每组40例,在控制饮食的同时观察组加用阿托伐他汀40mg,每日1次口服,治疗12周。比较两组患者治疗前后BNP水平。结果两组患者BNP水平均明显下降(P〈0.05),且观察组比对照组下降更为显著。结论阿托伐他汀能够明显降低患者的BNP水平,改善预后。 Objective To investigate the effect of atorvastatin on B-type natriuretic peptide (BNP) levels in patients with acute coronary syndrome. Methods Eighty patients with ACS hospitalized in our hospital from December 2010 to August 2011 were randomly divided into two groups:control group ( n = 40) and treatment group ( n = 40). Patients in the treatment group received atorvastatin 40 mg per day for twelve weeks on the basis of diet control. BNP levels were compared in the two groups before and after treatment. Results After the treatment, BNP levels of the two groups were obviously decreased (P 〈 0. 05), and was decreased more significantly in treatment group. Conclusions Atorvastatin can decrease the BNP level and improve the prognosis of patients with ACS.
出处 《中国实用医刊》 2012年第11期35-36,共2页 Chinese Journal of Practical Medicine
关键词 阿托伐他汀 急性冠状动脉综合征 B型钠尿肽 Atorvastatin Acute coronary syndrome B-type natriuretic peptide
  • 相关文献

参考文献7

  • 1胡大一;杨振华.B型钠尿肽的临床应用和最新进展[M]北京:北京科学技术出版社,200629-102.
  • 2Nozaki T,Sugiyama S,Koga H. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients af high risk for coronary heart disease[J].Journal of the American College of Cardiology,2009,(07):601-608.doi:10.1016/j.jacc.2009.05.022.
  • 3Cameron SJ,Sokoll LJ,Laterza OF. A multi-marker approach for the prediction of adverse events in patients with acute coronary syndromes[J].Clinica Chimica Acta,2007,(1-2):168-173.doi:10.1016/j.cca.2006.08.019.
  • 4Harvey D,White HD,French JK. Use of brain natriuretic peptide levels for risk assessement in non-ST-elevatio acute coronary syndrome[J].Am Coll Cardio1,2003,(11):1917-1920.doi:10.1016/j.jvs.2009.06.019.
  • 5Morrow DA,de Lemos JA,Sabatine MS. Evaluation of B-type natriuretic peptide for risk assessment in unstable Angina/Non-ST-elevation myocardial infraction:B-type natriuretic Peptide and prognosis in TACTICS-TIMI 18[J].Journal of the American College of Cardiology,2003,(08):1264-1272.doi:10.1016/S0735-1097(03)00168-2.
  • 6林毅,罗助荣,盖晓波.不同剂量阿托伐他汀对2型糖尿病患者体内炎症的影响[J].心血管康复医学杂志,2007,16(4):380-382. 被引量:10
  • 7林毅,陈新民,罗助荣,盖晓波.不同剂量阿托伐他汀对急性冠脉综合征患者体内炎症反应、血小板活性及纤溶活性的影响[J].医学信息(西安上半月),2007,20(6):973-976. 被引量:18

二级参考文献21

  • 1吴国新,阮长耿.血小板颗粒膜蛋白研究进展[J].中华血液学杂志,1994,15(3):162-164. 被引量:231
  • 2尤巧英,李成江,李红,朱麒钱,斯徐伟.炎症因子与胰岛素抵抗和2型糖尿病大血管病变的相关性研究[J].中华流行病学杂志,2005,26(10):804-807. 被引量:27
  • 3Bustos C,Hernandez-Presa MA,Ortego M,et al.HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.J Am Coll Cardiol,1998,32:2057-2064.
  • 4Aikawa M,Rabkin E,Sugiyama S,et al.An HMG-CoA reductase inhibitor,cerivastatin,suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro.Circulation,2001,103:276-283.
  • 5Bourcier T,Libby P.HMG-CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells.Arterioscler Thromb Vasc Biol,2000,20:556-562.
  • 6Braunwald E,Antman EM,Beasley JW,et al.ACC/AHA Guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction.A report of American college of cardiology/American heart association task force on practice guidelines.J Am Coll Cardiol,2000,36 (3):970.
  • 7O' Malley T,Ludlam C A,Riemermsa R A,et al.Early increase in levels of soluble intercellular adhesion molecule-1 (sICAM-1),potential risk factor for the acute coronary syndromes[J].Eur Heart J,2001,22:1226-1234.
  • 8Pabon OP,Nieto BF,Morinigo MJ,et al.The effect of the mean platelet volume on the short-term prognosis of acute myocardial infarct[J].Revista Espahola de Cardiologia,1998,51(10):816-822.
  • 9Haverkate F.Level of haemostatic factor,arteriosclerosis and cardiovascular disease.Vascul Pharmacol,2002,39(3):109.
  • 10Rerolle IP,HertIg A,Nguyen G,et al.Plasminogen activator inhibitor-1 is a potential target in renal fibrogenesis.Kidney Int,2000; 58(5):1841-1850.

共引文献25

同被引文献39

  • 1黄伟光,韦建瑞,吴同果,陈思伟,孙爱华,梅克治.冠心病病人N端前脑钠肽检测的临床意义[J].岭南心血管病杂志,2007,13(5):337-339. 被引量:14
  • 2郑渊.氟伐他汀治疗冠心病并高脂血症428例分析[J].中国误诊学杂志,2006,6(23):4623-4624. 被引量:3
  • 3王红卫,喻卓,付先平.国产阿托伐他汀治疗冠心病并发高脂血症疗效观察[J].云南医药,2007,28(3):241-243. 被引量:7
  • 4Cannon CP,Braunwald E,McCabe CH,et al.Intensive versus moderate lipid lowering with statins after acute coronary syndromes[J].N Engl J Med,2004,350(15):1495-1504.
  • 5Tan J,Hua Q.Correlations between serum inflammation factors and left ventricular remodeling in acute ST segment elevation myocardial infarction[J].Yonsei Med J,2012,53(3):501-507.
  • 6Frasure-Smith N,Lespérance F,Irwin MR,et al.Depression,Creactive protein and two-year major adverse cardiac events in men after acute coronary syndromes[J].Biol Psychiatry,2007,62(4):302-308.
  • 7Mach F,Sch(o)nbeck U,Fabunmi RP,et al.T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD4o L-dependent mechanism:implications for tubule formation[J].Am J Pathol,1999,154(1):229-238.
  • 8Türker S,Güneri S,Akdeniz B,et al.Usefulness of preprocedural soluble CD4o ligand for predicting restenosis after percutaneous coronary intervention in patients with stable coronary artery disease[J].Am J Cardiol,2006,97(2):198-202.
  • 9Eren NK,Ertas F,Yüksek U,et al.Additive prognostic value of NT-proBNP over TIMI risk score in intermediate-risk patients with acute coronary syndrome[J].Turk Kardiyol Dern Ars,2009,37(1):1-8.
  • 10Yang YJ,Zhao JL,You SJ,et al.Post-infarction treatment with simvastatin reduces myocardial no-reflow by opening of the KATP channel[J].Eur J Heart Fail,2007,9(1):30-36.

引证文献6

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部